Metastatic ovarian tumor of a lung cancer at the hospital center of Chauny (France): a case report

Adjoby Cassou Roland¹, Kouamé Arthur Didier¹*, Koffi Achille¹, Kakou Charles¹, Konan Joachim¹, Andriamandimbison Zoly², Ahounkeng Patrick², Nshimirimana Eric²

¹Department of Obstetrics and Gynecology, University Hospital Center of Cocody, Abidjan, Côte d'Ivoire
²Department of Obstetrics and Gynecology, Hospital Center of Chauny, France

Received: 14 September 2017
Accepted: 16 September 2017

*Correspondence:
Dr. Kouamé Arthur Didier,
E-mail: Arthur.kouame@mail.huji.ac.il

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

The ovary is an organ that can be the site of metastases for many cancers. In general, malignant ovarian tumors are primary; however, cases of extra gynecological metastatic tumors (breast, colon, stomach, and pancreas) have been reported. In most cases, the primary cancers of these ovarian tumors are gastrointestinal or gynecological, the lung being very rarely involved. We report a rare case of ovarian metastases of bronchial cancer discovered during an extensional assessment. The histological examination coupled with immunohistochemistry concludes that ovarian metastasis of small cell lung carcinoma. In addition to chemotherapy such as Taxol-Hycamtin, the management required cerebral radiotherapy for a cerebral metastasis detected.

Keywords: Metastasis, Napsin A, Ovary, Small cell lung carcinoma

INTRODUCTION

Every year around the world, ovarian cancer is diagnosed in approximately 200,000 women and 115,000 women die from it.¹ Ovarian cancers are the sixth most common cancer in women and constitute 4% of cancer deaths occurring in the majority of cases in the post-menopausal period. Mortality rates in developed countries exceed 5 per 100,000 women.²

In general, malignant ovarian tumors are primary, although cases of metastatic extra gynecological tumors (breast, colon, stomach, pancreas) have been reported in 6% to 22% with a gastrointestinal predominance.³ Bronchial metastases represent 2% to 4% of metastatic ovarian tumors.⁴ We report a rare case of bronchial cancer with ovarian metastases and discuss the diagnostic and therapeutic aspects.

CASE REPORT

A 52-year-old patient is admitted to the Pneumology department of Chauny Hospital Center for investigation of recurrent pneumonia. This is a third 3rd gesture and 3rd parous woman who smoked 10 cigarettes per day for 17 years. She does not have a real gynecological follow-up. There is no oncological history in her family. In the course of respiratory system assessment, the chest CT scan showed a pre-atelectatic opacity, a left pleural reaction, with an infiltrate in the mediastinal region, associated with a repression of the right atrium and the left upper pulmonary vein (Figure 1). In PET SCAN, lymphadenopathy under hyperintense metabolic pathways is objectified with a left pulmonary hilar ganglio-tumor mass with moderately hypermetabolic pulmonary condensation downstream of the left hilar ganglio-tumor mass.
The bronchial fibroscopy performed was in favor of an infiltration with respect to the spur of the left lower lobe with stenosis at the entrance. A biopsy on a tumor area of the upper left lobe is done, and the histology concludes with small cell lung carcinoma. The treatment was based on 2 cycles of chemotherapy (Paclitaxel-Carboplatin-Doxorubicin-Endoxan), 2 cycles of carboplatin-VP16 and a radiochemotherapy Carboplatin-VP16. Relative clinical improvement was observed with encouraging results on MRI, PET-SCAN: reduction of the volume of infiltration, lymphangitis symptoms and the volume of the lymph node under carini.

Three months later, the patient consulted her gynecologist for heaviness pelvic pain. The gynecological examination found a left lateral uterine mass. A pelvic ultrasound carried out allows the visualization of an organic mass developed at the expense of the left ovary (Figure 2). Ovarian tumor markers check were normal (ACE = 1.13 ng/ml; CA 19-9 = 10 U/ml; CA 125 = 12 U/ml). A PET SCAN carried out for the work-up for extension showed a Hypermetabolic ovarian lesion with a strong suspicion of cerebral and left adrenal invasion. Laparoscopy revealed an inflammatory pelvis, adhesions preventing the right adnexa from being observed and an enlarged left ovary without extracystic vegetation.

Omentum and peritoneum biopsy, cytological specimens and left adnexectomy were performed. The histological report concludes that ovarian metastasis of a slightly differentiated bronchial cancer with a high mitotic activity (>50 mitoses/10champs), ki67 up to 60%, a strong intra nuclear positivity with TTF1 (Thyroid Transcription Factor-1) and negative anti chromogranin (Figures 3a, b and c).

Given this dark prognosis, cerebral radiotherapy and chemotherapy such as Taxol-Hycamtin (paclitaxel-topotecan) with CT scan and PET SCAN are planned after 3 cycles.

DISCUSSION

Bronchial cancer is a tumor with a high metastatic potential, with a predilection for the liver, the brain and the adrenal glands. Metastasis occurs through several mechanisms, including direct extension of neighboring organ cancer, transtubal migration of endometrial cancer, dissemination through the peritoneal fluid or by vascular invasion. Indeed, the absence of capsular invasion as well as the vascular, lymphatic or venous invasion supports a lymphatic and hematogenic pathways of extension.5,6
Its dissemination in the genital tract rarely occurs with variable effects in the literature; At an average age of 47 years with extremes of 26-76 years. In a North American study of 500 cases of ovarian tumors, 17% were metastatic versus 22% in a Turkish study of 186 cases of ovarian tumors. A large Chinese study of 10288 cases of metastatic ovarian tumors reported a bronchial origin in 10% of cases. Fujiwara et al., in an analysis of 313 patients with ovarian metastases, found only one case of primary bronchial cancer.

Metastatic ovarian cancers of non-gynecological origin are ten times more frequent than those from the genital tract, with adenocarcinomas of the gastrointestinal tract leading. In a recent study of 166 patients with non-gynecologic malignancies and adnexal masses, Kim et al. found 68% of ovarian metastases. These masses can be the first clinical manifestation of the malignant tumor, thus a source of diagnostic error of the true primary tumor, even after pathological examination. Indeed, an extra-genital primary cause was found in 17% after ovarian mass surgery and 38% in another study, in an interval of 4 days to 7 months. Some determinants of metastatic disease are known: high-grade tumor, diffuse peritoneal and omental involvement and invasion of retroperitoneal nodes. By itself, bronchial cancer is involved in 2-4%. However this rate is increasing. In cases already described, small cell carcinoma was the most histologic type reported (43%) followed by adenocarcinoma (32%), more rarely large cell carcinoma, composite carcinoma and atypical carcinoid tumor. Ketata et al. In a study, reported 37 cases of total ovarian metastases listed in various studies worldwide. In the diagnosis sequence, some authors initially observed metastases in six cases, synchronous discovery with the primary tumor in 16 cases and secondary to the discovery of the primary tumor in 15 cases. It is often unilateral (27 of 37 cases). In 10% of cases, coexistence of a primary and metastatic tumor was noticed on the ovary.

Clinical diagnosis of metastatic ovarian tumor is never easy; Often accidental discovery, but sometimes symptomatic with manifestations of palpable mass, menometrorrhagias or pelvic pain which was the case in our observation. Ultrasound is the first-line examination before a pelvic mass and will specify its cystic or solid nature (partitions, vegetations) wall state, vascularisation, existence of a peritoneal collection. MRI is currently the reference tool for characterizing the ovarian masses: cystic lesions appear in hyper signal T2 and hypo signal T1, whereas tissue lesions are intermediate signal and enhance after gadolinium injection.

In present study, imaging evoked an ovarian tumor. The exact nature was specified by pathological examination of a piece taken during an operative laparoscopy. Differentiation between primary and metastatic ovarian tumors remains problematic. In principle, tumor expression for TTF1 (thyroid, lung and diencephalon-specific gene transcription protein) and CA 125 negativity are in favor of a primary pulmonary tumor.

The diagnosis of small cell carcinomas is based on morphological and immunohistochemical data by expression of neuroendocrine markers (chromogranin and synaptophysin). In the immunohistochemical arsenal, another protein: Napsin A expressed on pneumocytes type II and alveolar macrophages, would be a complementary tool. It distinguishes primary bronchial adenocarcinomas from adenocarcinomas from other organs or metastatics. Thus, the combination of Napsin A and TTF-1 would increase sensitivity and specificity in the authentification of pulmonary origin of metastatic adenocarcinomas.

CONCLUSION

Clinicians should be mindful of a metastatic event before any ovarian tumor with atypical clinical and anatomicopathological features. Moreover, with the recrudescence of bronchial cancers in women, the pulmonary origin of the metastatic ovarian masses should be sought and in this approach TTF-1 would be unavoidable.

ACKNOWLEDGMENTS

Authors would like to thank patient for giving her consent to publish the case.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES
